Press Release

Tizona Elects Daniel K. Spiegelman To Its Board Of Directors

SOUTH SAN FRANCISCO, Calif., May 15, 2019 — Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board of Directors. Mr. Spiegelman is currently Executive Vice President and Chief Financial Officer of BioMarin Pharmaceutical Inc.

“Dan brings a wealth of industry experience to Tizona’s Board, and his insights and guidance will be of great value as we advance our pipeline through development and eventually, commercialization,” said Scott Clarke, CEO of Tizona. “I had the pleasure of working with Dan in my previous role at BioMarin and have first-hand exposure to the depth of his experience in helping growing companies navigate the complex financial and commercial aspects unique to biotechnology. We are thrilled to welcome him as an important addition to our Board.”

Prior to joining BioMarin in May 2012, Mr. Spiegelman served as a strategic and financial consultant to a portfolio of public and private life science companies from May 2009 to May 2012. From 1998 to 2009, he served as Senior Vice President and Chief Financial Officer of CV Therapeutics where he was responsible for Finance, Accounting, Investor Relations, Business Development and MIS. From 1991 to 1998, Mr. Spiegelman served in various roles at Genentech, Inc., (now a member of the Roche Group) most recently as Treasurer. He received a Bachelor of Arts degree from Stanford University and an MBA from the Stanford Graduate School of Business.

About Tizona Therapeutics, Inc.

Tizona Therapeutics is a privately held, clinical-stage immunotherapy company committed to developing first-in-class therapeutics that deliver radical shifts in cancer treatment. Through strategic partnerships and its own scientific expertise, Tizona applies novel human biological insights to address cancer progression and relapse by developing biotherapeutics that stimulate the immune system and counter immune suppression. In addition to TTX-030, Tizona has several preclinical product candidates targeting other pro-inflammatory and anti-inflammatory signals that regulate the immune system’s function. For more information, visit


Tizona Corporate Communications
Cooper Communication Group
Tara Cooper